Physician profile
Joel Hunter
NPI 1952590978
$1,019.21
in general payments reported to CMS, 2019-2025
10 companies · $365 in 2025
The $365 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $61.73 · 2022: $60.34 · 2023: $162 · 2024: $370 · 2025: $365.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $840 · Honoraria: $38.86 · Education: $17.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $840.44 |
| Honoraria | $38.86 |
| Education | $17.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Rxsight INC | $502.06 | 2023-2025 | Rxsight Light Delivery Device (Ldd), Rxsight Injector Handpiece, Rxsight Injector Cartridge |
| Alcon Vision LLC | $165.98 | 2022-2025 | Wavelight Ex500 Excimer Laser, Clareon |
| Glaukos Corporation | $71.87 | 2022-2025 | Kxl System (Not Refurbished), Ce-Marked Kxla System |
| Rayner Intraocular Lenses Limited | $55.75 | 2023 | Rayone Aspheric, Rayone Emv, Omidria |
| Johnson & Johnson Surgical Vision, INC. | $53.16 | 2019-2023 | Tecnis Iol, Tecnis Simplicity |
| Bausch & Lomb Americas INC. | $52.44 | 2023-2024 | Envista Mx60 Iol, Miebo |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $44.94 | 2019 | |
| Carl Zeiss Meditec USA, INC. | $34.67 | 2024 | Quatera 700 |
| Dompe US, INC. | $22.71 | 2025 | Oxervate |
| Horizon Therapeutics Plc | $15.63 | 2023 | Tepezza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joel Hunter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.